2 research outputs found
Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy
ERα and CYP19 polymorphisms affect the therapeutic outcome of docetaxel in patients with castrationresistant prostate cancer (CRPC) and are associated with CRPC risk